CANCELLED: Health Law Seminar Series: Belinda Bennet

THIS WORKSHOP HAS BEEN CANCELLED

HEALTH LAW SEMINAR SERIES

presents 

Belinda Bennet
Professor, Faculty of Law
Queensland University of Technology (Australia)

Pandemics, Plans and the Public: Regulatory Discourses in Global Health

 

Health Law Seminar Series: John Dawson

Health Law Seminar Series
presents

John Dawson
Faculty of Law, University of Otago
 

Randomized Controlled Trials of Community Treatment Order Regimes
 

Commentator:
Tess Sheldon, PhD Candidate
Dalla Lana School of Public Health, University of Toronto

Health Law Seminar Series: Obaka Ogbogu

HEALTH LAW SEMINAR SERIES

presents


Obaka Ogbogu
Assistant Professor
Faculties of Law and Pharmacy
University of Alberta

The Return of Vaccine-Preventable Diseases:
Why Mandatory Immunization is the Right Policy Option

European Medicines Agency's Proposed Data Release Policy: Promoting Pharma's Control Over Data

Trudo Lemmens
Friday, May 30, 2014

[Note: this Blog was originally written for and appeared as Guest Blog in PLoS' Blog "Speaking Of Medicine" (May 30, 2014) Reproduced here with permission]

Things were looking good recently in Europe for data transparency, a necessary, albeit not sufficient, tool to promote integrity of pharmaceutical data. The European Court’s Vice-President overturned in November 2013 two lower court interim suspensions of EMA’s data access decision in relation to Abbvie’s drug Humira and Intermune’s Esbriet, which had stalled EMA’s data release approach. Shortly after, Abbvie withdrew the Humira lawsuit. Then in April 2014, the European Parliament approved the new Clinical Trials Regulation that introduced a requirement to register all clinical trials and make all clinical study reports in relation to EMA approved drugs publicly available. These developments put EMA again in the driver’s seat for the further implementation of its promised prospective data release policy.

Pages